| アブストラクト | The aim of this non-interventional, multi-database, analytical cohort study was to assess the cardiovascular (CV) safety of vildagliptin vs other non-insulin antidiabetic drugs (NIADs) using real-world data from 5 European electronic healthcare databases. Patients with type 2 diabetes aged >/=18 years on NIAD treatment were enrolled. Adjusted incidence rate ratios (IRRs) and 95% confidence intervals (CIs) for the outcomes of interest (myocardial infarction [MI], acute coronary syndrome [ACS], stroke, congestive heart failure [CHF], individually and as a composite) were estimated using negative binomial regression. Approximately 2.8% of the enrolled patients (n = 738 054) used vildagliptin at any time during the study, with an average follow-up time of 1.4 years, resulting in a cumulative current vildagliptin exposure of 28 330 person-years. The adjusted IRRs (vildagliptin [+/-other NIADs] vs other NIADs) were in the range of 0.61 to 0.97 (MI), 0.55 to 1.60 (ACS), 0.02 to 0.77 (stroke), 0.49 to 1.03 (CHF), and 0.22 to 1.02 (composite CV outcomes). The IRRs and their 95% CIs were close to 1, demonstrating no increased risk of adverse CV events, including the risk of CHF, with vildagliptin vs other NIADs in real-world conditions. |
|---|
| ジャーナル名 | Diabetes, obesity & metabolism |
|---|
| 投稿日 | 2017/3/25 |
|---|
| 投稿者 | Williams, Rachael; de Vries, Frank; Kothny, Wolfgang; Serban, Carmen; Lopez-Leon, Sandra; Chu, Changan; Schlienger, Raymond |
|---|
| 組織名 | Clinical Practice Research Datalink, London, UK.;Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, The;Netherlands.;Department of Clinical Pharmacy and Toxicology, Maastricht University Medical;Centre+, Maastricht, The Netherlands.;Novartis Pharma AG, Basel, Switzerland.;Novartis Pharmaceuticals Corporation, East Hanover, New Jersey.;Sanofi-Aventis US LLC, Bridgewater, New Jersey. |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/28338281/ |
|---|
